Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients

We evaluated microvessel density (MVD) in bone marrow biopsies (BM) from multiple myeloma (MM) patients after staining with anti‐CD34 and anti‐CD105 antibodies (mAbs). The anti‐CD105 mAb was significantly more sensitive than the anti‐CD34 mAb in visualizing blood vessels both in controls and MM samp...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2002-09, Vol.118 (3), p.817-820
Main Authors: Pruneri, Giancarlo, Ponzoni, Maurilio, Ferreri, Andrés J. M., Decarli, Nicola, Tresoldi, Moreno, Raggi, Francesca, Baldessari, Chiara, Freschi, Massimo, Baldini, Luca, Goldaniga, Maria, Neri, Antonino, Carboni, Nadia, Bertolini, Francesco, Viale, Giuseppe
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Angiogenesis
Antibodies, Monoclonal - immunology
Antigens, CD
Antigens, CD34 - analysis
Biological and medical sciences
Biomarkers, Tumor - analysis
Biopsy
Blood vessels
Bone marrow
CD105
CD34
CD34 antigen
Endoglin
Female
Follow-Up Studies
Hematology
Humans
Immunodeficiencies. Immunoglobulinopathies
Immunoglobulinopathies
Immunopathology
Male
Medical sciences
Microcirculation
Middle Aged
Monoclonal antibodies
Multiple myeloma
Multiple Myeloma - blood supply
Multivariate Analysis
Neovascularization, Pathologic - pathology
Prognosis
Receptors, Cell Surface
Survival
Survival Rate
Vascular Cell Adhesion Molecule-1 - analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated microvessel density (MVD) in bone marrow biopsies (BM) from multiple myeloma (MM) patients after staining with anti‐CD34 and anti‐CD105 antibodies (mAbs). The anti‐CD105 mAb was significantly more sensitive than the anti‐CD34 mAb in visualizing blood vessels both in controls and MM samples. MVD was significantly higher in MM than in controls with both anti‐CD34 and anti‐CD105 mAbs. Patients with low CD34+ MVD survived longer than patients with higher MVD (P = 0·01), whereas there was no difference in survival between patients with low and high CD105+ MVD. Multivariate analysis confirmed the independent significant association between CD34+ MVD and survival (P = 0·001).
ISSN:0007-1048
1365-2141
DOI:10.1046/j.1365-2141.2002.03654.x